☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Bipolar Disorders I and II
BioXcel Reports the US FDA's Acceptance of BXCL501's NDA for the Acute Treatment of Agitation Associated with Schizophrenia and Bi...
May 19, 2021
Load more...
Back to Home